- Home
- ZDAI vs INAB Comparison
ZDAI vs INAB Comparison
Compare ZDAI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZDAI | INAB |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | Hong Kong | United States |
| Employees | 33 | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 13.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZDAI | INAB |
|---|---|---|
| Price | $2.15 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 23.7K | ★ 49.2K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $1.17 |
| 52 Week High | $11.48 | $2.73 |
Technical Indicators
Market Signals| Indicator | ZDAI | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.72 | 37.78 |
| Support Level | $1.74 | $1.34 |
| Resistance Level | $2.52 | $1.85 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 21.56 | 9.52 |
Price Performance
Historical ComparisonAbout ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.